UK markets open in 56 minutes

Viatris Inc. (0A5V.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
9.85-0.22 (-2.14%)
At close: 06:51PM BST
Full screen
Previous close10.06
Open9.94
BidN/A x N/A
AskN/A x N/A
Day's range9.93 - 9.95
52-week range8.44 - 12.30
Volume2
Avg. volume20,422
Market capN/A
Beta (5Y monthly)1.15
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings date06 May 2024 - 10 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire

    Viatris Appoints Corinne Le Goff as Chief Commercial Officer

    Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that Corinne Le Goff has joined the company as Chief Commercial Officer and will become a member of the company's Executive Leadership Team, effective today.

  • GlobeNewswire

    Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris

    FARMINGTON HILLS, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of unmet needs of patients with retinal and refractive eye disorders, today announced the U.S. commercial launch of RYZUMVI™ (phentolamine ophthalmic solution) by its partner Viatris Inc. (NASDAQ: VTRS). Ocuphire has a global license agreement with Viatris to co-develop and commercialize Phentolamine O

  • PR Newswire

    Viatris Announces the Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% in the United States

    Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the U.S. commercial launch of RYZUMVI™ (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents in the United States. RYZUMVI is now the only U.S. commercially available FDA-approved eye drop to reverse dilation.1